Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014

JAMA Pediatrics

Volumn 171, Issue 8, 2017, Pages 747-755

  Hadland, Scott E ^a,b,c,d   Frank Wharam, J W ^d,e   Schuster, Mark A ^c,d   Zhang, Fang ^d,e   Samet, Jeffrey H ^b   Larochelle, Marc R ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NALTREXONE;

ADOLESCENT; ADULT; AGE; BLACK PERSON; CAUCASIAN; COHORT ANALYSIS; DRUG DEPENDENCE TREATMENT; FEMALE; HEALTH CARE DISPARITY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SEX DIFFERENCE; TIME; TREND STUDY; UNITED STATES; YOUNG ADULT; EPIDEMIOLOGY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT ATTITUDE; PREVALENCE; STATISTICS AND NUMERICAL DATA; TRENDS;

ADOLESCENT; BUPRENORPHINE; COHORT STUDIES; FEMALE; HUMANS; MALE; NALTREXONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT ACCEPTANCE OF HEALTH CARE; PREVALENCE; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 85027277556     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2017.0745     Document Type: Review

References (50)

1. Warner M, Hedegaard H, Chen LH. Trends in Drug-Poisoning Deaths: United States, 1999-2012. Atlanta, GA: National Center for Health Statistics; 2014.
2. Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS Data Brief. 2014; (166):1-8.
3. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659.
4. Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(3):241-248.
5. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths-United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50-51):1378-1382.
6. Gaither JR, Leventhal JM, Ryan SA, Camenga DR. National trends in hospitalizations for opioid poisonings among children and adolescents, 1997 to 2012. JAMA Pediatr. 2016;170(12):1195-1201.
7. Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality. The DAWN Report: Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. Rockville, MD: Drug AbuseWarning Network; 2013.
8. Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2003-2013 National Admissions to Substance Abuse Treatment Services. Rockville, MD: Drug Abuse Warning Network; 2015.
9. Zibbell JE, Iqbal K, Patel RC, et al; Centers for Disease Control and Prevention. Increases in hepatitis C virus infection related to injection drug use among persons aged 30 years-Kentucky, Tennessee, Virginia, andWest Virginia, 2006-2012. MMWRMorb Mortal Wkly Rep. 2015;64(17):453-458.
10. Johnston LD, O'Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the Future National Survey Results on Drug Use, 1975-2016: Overview, Key Findings on Adolescent Drug Use. Ann Arbor, MI: Institute for Social Research, The University of Michigan; 2017.
11. Levy SJ, Williams JF; Committee on Substance Use and Prevention. Substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016;138(1):e20161211-e20161211.
12. Centers for Disease Control and Prevention. HIV Among Youth. Atlanta, GA: Centers for Disease Control and Prevention; 2016.
13. Han B, Hedden SL, Lipari R, Copello EAP, Kroutil LA. Receipt of Services for Behavioral Health Problems: Results from the 2014 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Administration; 2015.
14. Cummings JR, Wen H, Ko M, Druss BG. Race/ethnicity and geographic access to Medicaid substance use disorder treatment facilities in the United States. JAMA Psychiatry. 2014;71(2):190-196.
15. Saloner B, Stoller KB, Barry CL. Medicaid coverage formethadone maintenance and use of opioid agonist therapy in specialty addiction treatment. Psychiatr Serv. 2016;67(6):676-679.
16. Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: A randomized controlled trial. Arch Gen Psychiatry. 2005;62(10): 1157-1164.
17. Fudala PJ, Bridge TP, Herbert S, et al; Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349(10):949-958.
18. Krupitsky E, Nunes EV, LingW, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377 (9776):1506-1513.
19. Marsch LA, Moore SK, Borodovsky JT, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction. 2016;111 (8):1406-1415.
20. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA. 2008;300(17):2003-2011.
21. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med. 2015;9(5):358-367.
22. Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann FamMed. 2015;13(1):23-26.
23. Center for Substance Abuse Treatment. Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series, No. 40. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
24. Substance Abuse and Mental Health Services Administration. National Expenditures for Mental Health Services and Substance Abuse Treatment 1986-2009. HHS Publication No. SMA-13-4740. Rockville, MD: Substance Abuse and Mental Health Administration; 2013.
25. Committee on Substance Use and Prevention. Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016;138(3): E20161893.
26. 2015 National Drug Control Strategy. Washington, DC: Office of National Drug Control Policy; 2015.
27. Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. Washington, DC: US Department of Health and Human Services (HHS) Office of the Surgeon General; 2016.
28. Stein BD, Gordon AJ, Sorbero M, Dick AW, Schuster J, Farmer C. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: Recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend. 2012;123(1-3):72-78.
29. Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV. Race/ethnicity, gender, and monitoring socioeconomic gradients in health: A comparison of area-based socioeconomic measures-the public health disparities geocoding project. Am J Public Health. 2003;93(10):1655-1671.
30. US Census Bureau. Geographic Areas Reference Manual.Washington, DC: US Census Bureau; 1994.
31. US Census Bureau. 2000 Census of Population and Housing.Washington, DC; US Census Bureau; 2004.
32. Fiscella K, Fremont AM. Use of geocoding and surname analysis to estimate race and ethnicity. Health Serv Res. 2006;41(4, pt 1):1482-1500.
33. Stein BD, Pacula RL, Gordon AJ, et al. Where is buprenorphine dispensed to treat opioid use disorders?. the role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties. Milbank Q. 2015;93(3):561-583.
34. Saloner B, Carson N, Lê Cook B. Explaining racial/ethnic differences in adolescent substance abuse treatment completion in the United States: A decomposition analysis. J Adolesc Health. 2014;54 (6):646-653.
35. Cook BL, Alegría M. Racial-ethnic disparities in substance abuse treatment: The role of criminal history and socioeconomic status. Psychiatr Serv. 2011;62(11):1273-1281.
36. Sommers BD, Kronick R. The Affordable Care Act and insurance coverage for young adults. JAMA. 2012;307(9):913-914.
37. Winstanley EL, Steinwachs DM, Stitzer ML, Fishman MJ. Adolescent substance abuse and mental health: Problem co-occurrence and access to services. J Child Adolesc Subst Abuse. 2012;21(4): 310-322.
38. Lee JD, Nunes EV, Mpa PN, et al. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. Contemp Clin Trials. 2016;50:253-264.
39. Mericle AA, Arria AM, Meyers K, Cacciola J, Winters KC, Kirby K. National trends in adolescent substance use disorders and treatment availability: 2003-2010. J Child Adolesc Subst Abuse. 2015;24 (5):255-263.
40. Dick AW, Pacula RL, Gordon AJ, et al. Growth In buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11. Health Aff (Millwood). 2015;34(6):1028-1034.
41. Alegria M, Carson NJ, Goncalves M, Keefe K. Disparities in treatment for substance use disorders and co-occurring disorders for ethnic/racial minority youth. J AmAcad Child Adolesc Psychiatry. 2011;50(1):22-31.
42. Tuchman E. Women and addiction: The importance of gender issues in substance abuse research. J Addict Dis. 2010;29(2):127-138.
43. Wood E, Samet JH, Volkow ND. Physician education in addiction medicine. JAMA. 2013;310 (16):1673-1674.
44. Hadland SE, Wood E, Levy S. How the paediatric workforce can address the opioid crisis. Lancet. 2016;388(10051):1260-1261.
45. Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience. Arch Intern Med. 2011;171(5):425-431.
46. LaBelle CT, Han SC, Bergeron A, Samet JH. Office-based opioid treatment with buprenorphine (OBOT-B): Statewide implementation of the Massachusetts collaborative care model in community health centers. J Subst Abuse Treat. 2016;60:6-13.
47. Levy SJ, Kokotailo PK; Committee on Substance Abuse. Substance use screening, brief intervention, and referral to treatment for pediatricians. Pediatrics. 2011;128(5):e1330-e1340.
48. Jaffe JH, O'Keeffe C. From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2)(suppl):S3-S11.
49. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55-e63.
50. Abraham AJ, Rieckmann T, Andrews CM, Jayawardhana J. Health insurance enrollment and availability of medications for substance use disorders. Psychiatr Serv. 2017;68(1):41-47.